Advancing the science of OINDPs: Copley Scientific joins IPAC-RS

Nottingham, UK: Copley Scientific, a global leader in the design and manufacture of inhaler testing equipment, is pleased to announce that it has joined the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) as an Associate Member. IPAC-RS seeks to advance the science of orally inhaled and nasal drug products (OINDPs). As an Associate Member, Copley will actively participate in consortium working groups and knowledge networks, drawing on expertise accrued over decades working at the forefront of inhaler testing equipment development. With an emphasis on enhancement of the regulatory science associated with OINDPs, IPAC-RS directly supports the development of safer, more efficacious products for the treatment of respiratory illnesses such as asthma and chronic obstructive pulmonary disease.

“IPAC-RS plays a vital role in initiating and driving collaboration across the industry and we are looking forward to contributing to its work,’ said Mr Mark Copley, Director of Copley Scientific.” “Pulmonary drug delivery is uniquely complex and there remain considerable challenges for the community to address. A particular area of interest for us is the ongoing evolution of the test methods associated with delivered dose uniformity and aerodynamic particle size distribution measurements. These metrics define OINDP performance and are measured from R&D through to QC. Ensuring the associated methods and equipment are relevant, precise, and robustly fit-for-purpose is therefore crucial.”

IPAC-RS is comprised of leading innovator and generic companies working in the field of inhaled and nasal drug delivery. Through collaborative research and by building consensus amongst industry professionals, IPAC-RS enhances the regulatory framework for OINDPs, representing the community to regulatory agencies such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), Brazil National Health Surveillance Agency (ANVISA), and the China Food and Drug Administration (CFDA) as well as other key stakeholders including the pharmacopoeias and other standard setting bodies. IPAC-RS created the Associate Membership category to enable suppliers to OINDP manufacturers to participate in collaborative efforts to advance the science and regulation of these drug products.

“IPAC-RS welcomes Copley as an Associate Member. From our earliest days as a consortium, we have appreciated the perspectives and engagement of our supplier members and we look forward to Copley’s involvement,” says Robert Berger, IPAC-RS Chair.

To learn more about IPAC-RS go to:

To see Copley’s full range of equipment for inhaler testing, download “Quality Solutions for Inhaler Testing” from:

About Copley Scientific:

Copley Scientific is widely recognised as the world’s leading manufacturer and supplier of inhaler test equipment and is a major provider of testing systems for other pharmaceutical dosage forms. The company also supplies equipment for detergent testing.

Copley Scientific’s pharmaceutical product range includes test equipment for all types of orally inhaled and nasal drug products - metered-dose inhalers, dry powder inhalers, nebulizers and nasal sprays - with a particular focus on solutions for delivered dose uniformity and aerodynamic particle size distribution measurement. It also includes testers for tablets (dissolution, disintegration, friability and hardness) capsules, powders, suppositories, semisolids and transdermals.

Used from R&D through to QC, this extensive range of equipment is supported by a full validation and aftersales service. Copley Scientific has offices in the UK and Switzerland and works in partnership with aerosol particle science experts MSP Corporation in North America; specialist distributors extend localised support across the world. This network provides expert help and training to every customer, directly enhancing the application of all Copley Scientific products.


IPAC-RS is an international association that seeks to advance the science, and especially the regulatory science, of orally inhaled and nasal drug products (OINDPs) by collecting and analyzing data and conducting joint research and development projects. Members include innovator and generic companies that develop, manufacture or market OINDPs for local and systemic treatment of a variety of debilitating diseases such as asthma, chronic obstructive pulmonary disease and diabetes. Corporations that develop or manufacture components and/or devices for OINDPs or provide scientific or technical services relating to development and manufacture of OINDPs are eligible for participation in IPACRS as Associate Members. IPAC-RS aims to build consensus and contribute to effective regulations and standards by sharing the results of our research through conferences, technical journals, and discussions with regulatory bodies.

For further information:

Company contact:
Anna Sipitanou, Business Development Manager, Copley Scientific Limited
Colwick Quays Business Park, Private Road No. 2, Colwick, Nottingham
Tel: +44 (0)115 961 6229
Fax: +44 (0)115 961 7637

European Office (Austria, France, Germany, Italy, Switzerland)
Copley Scientific AG
Erlenstrasse 27, Postfach 152, CH-4106 Therwil, Switzerland
Tel: +41 (0)61 725 25 35
Fax: +41 (0)61 721 31 87